The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder

Steiner, Meir; Romano, Steven J.; Babcock, S. W.; Dillon, J.; Shuler, Cathy; Berger, Charlene; Carter, Diana; Reid, Robert L.; Stewart, Donna E.; Steinberg, Susanne; Judge, R.

doi:10.1016/s0306-5456(00)00120-0

Cited by 22 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment with selective serotonin reuptake inhibitors (SSRIs) induces a desensitization of hypothalamic and other forebrain 5-HT 1A receptors in both humans [17, 18, 59]and rats [13, 14, 15, 20, 60]. Mood disorders are more prevalent in women than in men; some of these, such as premenstrual dysphoric disorder, are most effectively treated with SSRIs [9, 61, 62, 63]. Additionally, SSRIs are more effective in relieving depression in women than norepinephrine reuptake inhibitors [64].…”

Section: Discussionmentioning

confidence: 99%

Ovariectomy-Induced Increases in Hypothalamic Serotonin-1A Receptor Function in Rats Are Prevented by Estradiol

Raap¹,

DonCarlos

García³

et al. 2002

Neuroendocrinology

View full text Add to dashboard Cite

The present study investigated the effects of long-term estradiol withdrawal (ovariectomy) on hypothalamic serotonin-1A (5-HT_1A) receptor signaling. Changes in neuroendocrine responses to the 5-HT_1A agonist 8-OH-DPAT and levels of G_z protein in the hypothalamus were used to examine 5-HT_1A receptor signaling. Five days following ovariectomy, rats received daily injections of either 2 µg of β-estradiol 3-benzoate or vehicle (subcutaneously) for 2, 4 or 14 days. Twenty-four hours after the last injection, and 15 min prior to sacrifice, rats were injected with (±)8-OH-DPAT (50 µg/kg, s.c.) or saline. Estradiol treatment did not alter basal corticotropin (ACTH) or oxytocin levels. Injection of (±)8-OH-DPAT produced significant increases in plasma ACTH and oxytocin levels. In the vehicle-treated rats, hormone responses to 8-OH-DPAT were enhanced in rats that received injections for 14 days compared with rats that received injections for either 2 or 4 days. Estradiol treatment for 4 or 14 days blunted this enhanced ACTH response to 8-OH-DPAT, whereas the oxytocin response to 8-OH-DPAT was only blunted after 14 daily injections of β-estradiol 3-benzoate. The treatment with β-estradiol 3-benzoate (2 µg/rat) did not reduce membrane-associated G_z protein levels in the paraventricular nucleus of the hypothalamus. Hence, the inhibitory influence of a low dose of β-estradiol 3-benzoate on 5-HT_1A receptor signaling in the hypothalamus is not accompanied by a change in the levels of G_z protein in the paraventricular hypothalamic nucleus. Results from the present study indicate a supersensitivity of 5-HT_1A receptors after withdrawal of estradiol and suggest that estradiol suppresses 5-HT_1A receptor signaling.

show abstract

Section: Discussionmentioning

confidence: 99%

Ovariectomy-Induced Increases in Hypothalamic Serotonin-1A Receptor Function in Rats Are Prevented by Estradiol

Raap¹,

DonCarlos

García³

et al. 2002

Neuroendocrinology

View full text Add to dashboard Cite

show abstract

“…124,145 Clinical experience suggests that most but not all women with PMS prefer intermittent treatment to continuous. SRIs administered intermittently, however, seem less effective for somatic symptoms than for mood symptoms, 119,120,125,146 and less effective for somatic symptoms than is continuous treatment. 125 Side-effects of SRIs are usually mild.…”

Section: Serotonin Reuptake Inhibitors (Sris)mentioning

confidence: 95%

Premenstrual syndrome

2008

View full text Add to dashboard Cite

Most women of reproductive age have some physical discomfort or dysphoria in the weeks before menstruation. Symptoms are often mild, but can be severe enough to substantially affect daily activities. About 5-8% of women thus suffer from severe premenstrual syndrome (PMS); most of these women also meet criteria for premenstrual dysphoric disorder (PMDD). Mood and behavioural symptoms, including irritability, tension, depressed mood, tearfulness, and mood swings, are the most distressing, but somatic complaints, such as breast tenderness and bloating, can also be problematic. We outline theories for the underlying causes of severe PMS, and describe two main methods of treating it: one targeting the hypothalamus-pituitary-ovary axis, and the other targeting brain serotonergic synapses. Fluctuations in gonadal hormone levels trigger the symptoms, and thus interventions that abolish ovarian cyclicity, including long-acting analogues of gonadotropin-releasing hormone (GnRH) or oestradiol (administered as patches or implants), effectively reduce the symptoms, as can some oral contraceptives. The effectiveness of serotonin reuptake inhibitors, taken throughout the cycle or during luteal phases only, is also well established.

show abstract

“…During the luteal phase, women with a MRMD show equivalent impairment in quality of life as patients with major depression, posttraumatic stress disorder (PTSD), or panic disorder (Freeman & Sondheimer, 2003). Although emotional symptoms are the diagnostic hallmark of MRMDs, somatic symptoms are prevalent and contribute to functional impairment (Steiner et al, 2001). Women with a MRMD are more likely to have a history of both physical and sexual abuse (Girdler et al, 2003(Girdler et al, , 2007Golding, Taylor, Menard, & King, 2000), and women with a MRMD are more sensitive to experimental pain stimuli than controls (Fillingim et al, 1997;Straneva et al, 2002).…”

mentioning

confidence: 99%

Menstrually related mood disorders and a history of abuse: Moderators of pain sensitivity.

Fleischman¹,

Bunevičius²,

Leserman³

et al. 2014

Health Psychology

View full text Add to dashboard Cite

Menstrually related mood disorder status moderates the effect of a history of abuse on pain sensitivity. The results also suggest that the hypocortisolemia documented in the women with a MRMD and an abuse history may contribute to their greater sensitivity to noxious pain stimuli. This study adds to a growing body of evidence suggesting that a history of abuse may identify a clinically distinct subgroup of women with a MRMD.

show abstract

The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder

Cited by 22 publications

References 30 publications

Ovariectomy-Induced Increases in Hypothalamic Serotonin-1A Receptor Function in Rats Are Prevented by Estradiol

Ovariectomy-Induced Increases in Hypothalamic Serotonin-1A Receptor Function in Rats Are Prevented by Estradiol

Premenstrual syndrome

Menstrually related mood disorders and a history of abuse: Moderators of pain sensitivity.

Contact Info

Product

Resources

About